BDBM569331 US11427563, Compound 17::US11427563, Compound 87

SMILES CCc1cncc2ccc(NC(=O)[C@@H]3CC3c3ccc(cc3)S(=O)(=O)Nc3ccccn3)cc12

InChI Key InChIKey=ZPRHGJOOCBVZCP-UHFFFAOYSA-N

Data  11 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 569331   

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569331(US11427563, Compound 17 | US11427563, Compound 87)
Affinity DataIC50: 0.800nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569331(US11427563, Compound 17 | US11427563, Compound 87)
Affinity DataIC50: 0.800nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569331(US11427563, Compound 17 | US11427563, Compound 87)
Affinity DataIC50: 2.70nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569331(US11427563, Compound 17 | US11427563, Compound 87)
Affinity DataIC50: 4.20nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569331(US11427563, Compound 17 | US11427563, Compound 87)
Affinity DataIC50: 4.30nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569331(US11427563, Compound 17 | US11427563, Compound 87)
Affinity DataIC50: 12nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569331(US11427563, Compound 17 | US11427563, Compound 87)
Affinity DataIC50: 19nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569331(US11427563, Compound 17 | US11427563, Compound 87)
Affinity DataIC50: 44nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569331(US11427563, Compound 17 | US11427563, Compound 87)
Affinity DataIC50: 44nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569331(US11427563, Compound 17 | US11427563, Compound 87)
Affinity DataIC50: 45nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569331(US11427563, Compound 17 | US11427563, Compound 87)
Affinity DataIC50: 45nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
US Patent